KRAS and neoplasm: Our study demonstrates that MHC-I peptides derived from covalently modified intracellular proteins provide an unique source of tumor-specific neoantigens which require presence of a somatic KRAS G12C mutation and its modification by a covalent KRAS G12C specific drug.